Ballard Power's Cautious Climb: Why a 'Hold' Rating Signals Reduced Risk, Not Immediate Riches
Biohaven's Balancing Act: Cash Cushion Grows, But So Does the Dilution Shadow
Xilio Therapeutics Soars 8% on Groundbreaking Cancer Drug Data and Strategic Gilead Investment